A protein called UBQLN2 is key for regulating both proteins and fat molecules in nerve cells, and disruptions in these activities — particularly the regulation of fat molecules — may play key roles in driving amyotrophic lateral sclerosis (ALS), a study found. The findings indicate that it may be…
News
Higher blood levels of the pollutant hexachlorobenzene (HCB), once widely used as a pesticide and later restricted in many countries due to concerns about toxicity, may increase the risk of developing amyotrophic lateral sclerosis (ALS), according to data from people living in two cities in Denmark. In contrast, most…
Swallowing difficulties are a common challenge for people with amyotrophic lateral sclerosis (ALS) and may place a substantial burden on patients during hospital stays, according to an analysis of a large U.S. database. The study found that about one-third of hospitalized ALS patients experienced difficulty swallowing (dysphagia), and…
Two blood markers indicative of inflammation and cellular stress may help predict disease progression patterns and survival in people with amyotrophic lateral sclerosis (ALS), a study found. Higher levels of these two markers, LBP and 4-HNE, “were correlated with a more rapid disease progression rate, shorter survival, and [worse…
Caregivers across Canada can now access free professional mental health support specifically tailored to the unique challenges of caring for people with amyotrophic lateral sclerosis (ALS). Expanding on a successful pilot project launched in Ontario last year, the ALS Society of Canada (ALS Canada) is rolling out a…
Advocates and lawmakers are racing against a looming September deadline to prevent a “funding cliff” for critical amyotrophic lateral sclerosis (ALS) research and treatment access. The ALS Association is now throwing its full weight behind the newly reintroduced ACT for ALS Reauthorization Act (H.R. 8205), a bipartisan push…
Shionogi has completed its acquisition of global rights to Radicava and Radicava ORS, two edaravone formulations approved to treat amyotrophic lateral sclerosis (ALS), from Tanabe Pharma, finalizing a deal announced late last year. When it signed the agreement, Tanabe said it would establish a U.S.-based company to…
A large-scale genetic analysis has identified several new rare mutations linked to amyotrophic lateral sclerosis (ALS), with findings suggesting that about a quarter of patients have an identifiable genetic contributor to their disease, according to a new study. The results, which come from an analysis of nearly 18,000 people…
People living with amyotrophic lateral sclerosis (ALS) in the U.S. generally prefer care models where they can see multiple healthcare providers during the same visit, rather than only regularly seeing a neurologist who refers them to other doctors as needed, according to a new study. The findings have important…
Up to six people with advanced amyotrophic lateral sclerosis (ALS) will be treated with Trethera’s experimental therapy TRE-515 under a collaboration with Massachusetts General Hospital (MGH). The patients will receive the oral treatment through a U.S. Food and Drug Administration (FDA) expanded access program (EAP), which allows people…
Recent Posts
- A novel helped me process heavy questions I face as an ALS caregiver
- Study links protein, fat regulator to nerve cell damage in ALS
- We must each find our own way as we learn to live with ALS
- Exposure to pesticide HCB may raise risk of ALS, new study finds
- Swallowing problems affect 1 in 3 hospitalized ALS patients: Study